CNDD labPharmacoengineering and Molecular pharmaceutics represent interdisciplinary specialties within the pharmaceutical sciences and encompass a range of scientific endeavors, including:

  • the design, fabrication, and evaluation of dosage forms and delivery strategies for conventional and biotechnology-based therapeutic agents;
  • elucidation of barriers to systemic and target-specific drug delivery;
  • determination of the ability of pharmacologic agents to reach the relevant site of biologic effect; and
  • determination of the time course of biologic activity.

These areas of specialization represent critical steps in the development of new therapeutic agents, the evaluation of new and existing agents in a variety of settings (e.g., potential interactions with other agents or alterations secondary to physiologic changes associated with disease processes), and the optimal clinical use of pharmacologic agents.

CNDDCenter for Nanotechnology in Drug Delivery

The CNDD, part of a campus-wide nanomedicine initiative at UNC, brings together scientists to create nano-scale pharmaceutical innovations for therapeutic and diagnostic purposes.

Recent Grants

Development of needle-free, multi-formulation nanoparticle vaccine

DTRA Keane-Myers/Ainslie (PI) 05/2013 – 05/2017

The major goal of this grant is to encapsulate bioterrorism agent vaccine agents and test them for needle-free delivery.

Celecoxib Derivative: Host Cell-Directed Inhibitors of Intracellular Pathogens

R21 AI102252 N/L 07/2012 – 06/2017

The major goal of this grant is to use a novel antibiotic that is currently used in clinical trials against cancer as an antibiotic against the bacteria that cause tuberculosis, rabbit fever and salmonella.

Use of Autologous Macrophages for Sustained Delivery of GDNF as Treatment of Parkinson’s Disease

UNC TEG15-4849 E. Batrakova (PI) 09/01/2015 – 06/30/2016

Polypeptide Modification for Enhanced Brain Delivery

2 R01 NS051334 NIH/NINDS, Kabanov (PI) Batrakova (Co-I) 01/01/2010 – 2015

Integrate Immune, Biomaterial & Stem Cell Platform for Neuroprotection in Battlefield Injuries

W81XWH11-1-0700 DoD, Kabanov (PI) Batrakova (Co-I) 08/29/2011 – 08/28/2014

Program in PharmacoEngineering: Integrating Engineering with Pharmaceutical Sciences to Improve the Delivery of Therapeutic and Diagnostic Agents

M. Jay (PI); Ligler (Co-PI); S. Hingtgen (Co-PI) 06/01/2015 – 06/01/2018

The goal of this project is to develop heterogeneous scaffolding materials designed to optimize the retention, persistence, and migration of tumoricidal neural stem cells transplanted into the GBM resection cavity.

Transdifferentiation: A novel Approach to Personalized Cancer Therapy

 Eshelman Institute for Innovation S. Hingtgen (PI) 11/01/2015 – 06/01/2018

The goal of this project is to advance iNSC therapy for GBM towards human patient testing by developing multiple strategies for iNSC generation, therapy, and characterization that will enable use in the clinical setting.
Light-Triggered Cell-Mediated Targeting of Glioblastoma

 Eshelman Institute for Innovation S. Hingtgen (PI) 11/01/2015 – 06/01/2018

The goal of this project is to create a new approach to cancer therapy where small molecule drugs are released from stem cell drug carriers using light activation.
Generation of Novel Patient-specific Induced Neural Stem Cell Carriers for Cancer Therapy

UNC University Research Council Award, S. Hingtgen (PI) 01/01/2013 – 11/30/2015

The goal of this small research grant is to cover the expense of deriving and culturing induced neural stem cell carriers generated from the skin of brain cancer patients.

UNC Clinical Translational Science Award-K12 Scholars Program (KL2)

KL2TR000084 NIH/NCATS, Runge (PI) 11/1/2013 – 04/30/2018

The overall goal of this application is to combine the research strengths, resources and opportunities at UNC and new partner, RTI International, to build on the foundation established in the CTSA’s last five years. On this project, we are a Scholar. As such, we leverage the resources of the CTSA to advance our research toward clinics. I receive both didactic and direct research support to accomplish this goal.

Nanocrystals for the Treatment of Multidrug Resistance in Cancer

1 R01 CA149387 L. Huang (PI) 2014-2016

Nano Approaches to Modulate Host Cell Response for Cancer Therapy

1U54CA198999-01 L. Huang (Co-PI); J.E. Tepper (Co-PI) 2015-2020

Priming the Liver to Resist Metastasis of Colorectal Cancer

Eshelman Institute of Innovation L. Huang (Co-PI); Rihe Liu (Co-PI) 2015-2017

Nanoscale Metal-Organic Frameworks for Imaging and Therapy of Pancreatic Cancer

1U01 CA151455-01 L. Huang (Co-PI); Wenbin Lin and Jen Jen Yeh (PI) 2010-2015

Carolina Center for Cancer Nanotechnology Excellence

1U54 CA151652-01 NIH, Huang (PI of Project 2); Joe DeSimone (Center Director) 2010-2015

Novel Nanoparticles for siRNA Delivery

1R01CA149363 NIH, Huang (PI) 2010-2015

Hepatic Non-Viral Gene Therapy

1R01DK100664 NIH, Huang (PI) 2013-2018

Pharmacoengineering: Integrating Engineering with Pharmaceutical Sciences to Improve the Delivery of Therapeutic and Diagnostic Agents

UNC-GA M. Jay (Co-PI); Ligler (Co-PI) 02/15/2015-02/14/2018

This grant will fund two large projects related to immunoengineering and stem cell therapies for junior faculty, and will provide programmatic infrastructural support.

C2E2-An Orally Administered Radionuclide Decorporation Agent

1R44AI115751-01 N/L 07/01/2015-06/30/2017

This Direct-to-Phase II SBIR proposal is for IND-enabling work for a radionuclide decorporation drug.

Nanoformulation of the BDNF for the Treatment of Stroke

1R21NS088152-01A1 A.V. Kabanov (PI) 07/01/2015 – 06/30/2017

Innovative Research in Cancer Nanotechnology (IRCN): Targeted Core Shell Nanogels for Triple Negative Breast Cancer

U01CA198910-01 A.V. Kabanov (PI) 08/14/2015 – 07/31/2020

Carolina Cancer Nanotechnology Training Program (C-CNTP)

1T32CA196589-01 A.V. Kabanov (PI) 07/01/2015 – 06/30/2020

Nano Approaches to Modulate Host Cell Response for Cancer Therapy; Project 4: High Capacity Polymeric Micelle Therapeutics for Lung Cancer

1U54CA198999-01 A.V. Kabanov (PI, Project 4) 09/15/2015 – 07/31/2020

Liposomal Doxorubicin and Pluronic Combination for Cancer Therapy

R01CA184088 A.V. Kabanov (PI); W. Zamboni (Co-PI) 01/01/2015 – 12/31/2019

Nanoformulated Brain Derived Neurotrophic Factor (BDNF) for the Treatment of Rett Syndrome

HeART Award #3112 A.V. Kabanov (PI) 01/01/2015 – 12/31/2016

Chemical Design of Bionanomaterials for Medical Applications

11.G34.31.0004 Government of Russian Federation, Ministry of Education and Science of Russian Federation, A.V. Kabanov (PI) 11/01/2010 – 12/31/2012; competitively renewed 01/01/2012-12/31/2014

Polypeptide Modification for Enhanced Brain Delivery

RO1 NS051334 NIH, NINDS, A.V. Kabanov (PI), W. Banks (co-PI), E.V. Batrakova, S.V. Vinogradov (Co-Is) 05/05/2010 – 03/31/2015

NanoART Manufacture, Delivery and Pharmacokinetics for Optimizing Drug Adherence, Project 1

1PO1 DA028555-01A1 NIH/NIDA 1PO1H. Gendelman (PO1 PI), A.V. Kabanov (Project 1 PI, consultant, EAC member, after reallocation to UNC on 08.12) 07/15/2010 – 04/30/2015

High Capacity Nanocarriers for Cancer Chemotherapeutics

UO1 CA151806 NIH NCI, A.V. Kabanov (PI), H. Band, T.K. Bronich, R. Jordan, R. Luxenhofer, S. Raja (Co-I) 09/02/2010 – 07/31/2015

PRINT Butyrylcholinesterase (BuChE) Delivery

 HDTRA1-09-14-FRCWMD-BAA DTRA/DoD, Thrust Area 3, Topic C: Nanostructed Active Therapeutic Vehicles (NATV), J. DeSimone (PI), A. Kabanov (Co-PI) 07/01/2013 – 06/30/2017

Center for RNA Therapeutics and Biology

SkolTech Center for Research Education and Innovation (CREI), Skolkovo Foundation. D. Anderson (PI non-Russian Institution/Center Co-Director), A.V. Kabanov (PI Russian Institution/Center Co-Director), V. Kotelianski (SkolTech Center Director), P. Sharp, R. Langer, O. Dontsova, N. Klyachko, V. Chekhonin, M. Gelfand, T. Jacks, J. Horton, J. Goldstein, M. Brown, (Co-Is) 01/01/2014 – 12/31/2018

CAREER: Biophysical Investigations of Immune-Mediated Pathogen Trapping in Mucus

1151477 S. Lai (PI) 04/2012 – 03/2017

Harnessing Antibody-Mucin Interactions to Control Microbial Communities in the Gut

2013-39274 Packard Foundation, Lai (PI) 12/2013 – 11/2018

Research Program in Immunoengineering

NC General Assembly – Research Opportunities Initiative S. Lai (PI) 07/2015 – 06/2018

Engineered Antibodies with Carefully Tuned Mucin-Affinity for Enhanced Mucosal Protection

Eshelman Institute for Innovation S. Lai (PI) 10/2015 – 09/2018

Optimizing Plantibodies for Trapping HIV and HSV in Cervicovaginal Mucus

U19AI096398 NIAID, Lai (Project 3 co-PI), Anderson (PI) 07/2011 – 06/2016

CAREER: Biophysical Investigations of Immune-Mediated Pathogen Trapping in Mucus

ID 1151477 NSF, Lai (PI) 04/2012 – 03/2017

Harnessing Antibody-Mucin Interactions to Control Microbial Communities in the Gut

2013-39274 Packard Foundation, Lai (PI) 12/2013 – 11/2018

Muscle as a Platform for Type 2 Diabetes Treatment by Gene Delivery

R01DK090380 Xiao 04/01/11 – 03/31/16

Center for Advanced Renal Microscopic Analysis (UNC Probe Delivery Core)

P30DK079312-06 Juliano, Xiao: Co-I 08/20/12 – 06/30/17

Gene Delivery for Fukutin-Related Protein Deficiencies

R01 NS082536 NIH/NINDS, Xiao 04/01/13 – 03/31/17

Gene Delivery to Muscle and Nerve for Laminin-α2-Deficient MD (MDC1A)

1R01 NS079568 NIH/NINDS, Xiao 04/01/13 – 03/31/18

Recent Publications

  1. Collier MA, Peine KJ, Gautam S, Oghumu S, Varikuti S, Borteh H, Papenfuss TL, Sataoskar AR, Bachelder EM, Ainslie KM. “Host-mediated Leishmania donovani treatment using AR-12 encapsulated in acetalated dextran microparticles.” Int J Pharm. 2016 Jan 5;499(1-2):186-194.
  2. Gallovic MD, Montjoy DG, Collier MA, Do C, Wyslouzil BE, Bachelder EM, Ainslie KM. “Chemically modified inulin microparticles serving dual function as a protein antigen delivery vehicle and immunostimulatory adjuvant.” Biomater Sci. 2016 Jan 11.
  3. Duong AD, Collier MA, Bachelder EM, Wyslouzil BE, Ainslie KM. “One Step Encapsulation of Small Molecule Drugs in Liposomes via Electrospray-Remote Loading.” Mol Pharm. 2016 Jan 4;13(1):92-9.
  4. Hoang KV, Curry H, Collier MA, Borteh H, Bachelder E, Schlesinger LS, Gunn JS, Ainslie K. “Needle-free Delivery of Acetalated Dextran-Encapsulated AR-12 Protects Mice from Francisella tularensis Lethal Challenge. Antimicrob Agents Chemother. 2016 Jan 19.
  5. Chen N, Peine KJ, Bachelder EM, Ainslie KM. “Micro- and Nano-particulate Strategies for Antigen Specific Immune Tolerance to Treat Autoimmune Diseases.” Pharmaceutical Nanotechnology, 2015 3(2): 85-100.
  6. Schully KL, Sharma S, Peine KJ, Pesce J, Elberson MA, Fonseca ME, Prouty AM, Bell MG, Eric M. Bachelder EM, Ainslie KM*, Keane-Myers A. “Acetalated Dextran (Ac-DEX) microparticle encapsulated Burkholderia psedomallei proteins induce a potent T cell response and induce partial protection in a mouse model of melioidosis”. Int J Pharm. 2015 Sep 28;495(2):849-861.
  7. Gupta G, Peine KJ, Abdelhamid D, Snider H, Shelton AB, Rao, Kotha SR, Huntsman HC, Varikuti S, Oghumu S, Naman CB, Pan L, Parinandi NL, Papenfuss TL, Kinghorn AD, Bachelder EM, Ainslie KM, Fuchs JR, Satoskar AR. A Novel Sterol Isolated from a Plant Used by Mayan Traditional Healers Is Effective in Treatment of Visceral Leishmaniasis Caused by Leishmania donovani. ACS Infectious Diseases 2015 1 (10), 497-506.
  8. Hoang KV, Borteh HM, Rajaram MVS, Peine KJ, Curry H, Collier MA, Homsy ML, Bachelder EM, Gunn JS, Schlesinger LS, Ainslie KM. “Acetalated dextran encapsulated AR-12 as a host-directed therapy to control Salmonella infection” Int J Pharm. 2014 477(1–2): 334–343.
  9. Peine KJ, Guerau-de-Arellano M, Lee P, Kanthamneni N, Severin M, Probst GD, Peng H, Yang Y, Vangundy Z, Papenfuss TL, Lovett-Racke AE, Bachelder EM, Ainslie KM. “Treatment of Experimental Autoimmune Encephalomyelitis by Co-Delivery of Disease Associated Peptide and Dexamethasone in Acetalated Dextran Microparticles”. ACS Mol Pharm. 2014 Jan 16.
  1. Batrakova E.V. and Kim M.S. (2016) Development and Regulation of Exosome-based Therapy Products, WIREs Nanomedicine & Nanobiotechnology, under review.
  2. Haney M.H., Klyachko N.L., Zhao Y., Gupta R., He Z., Patel T., Piroyan A., Sokolsky M., Kabanov A.V., Batrakova E.V. (2015) Exosomes as Drug Delivery Vehicles for Parkinson’s Disease Therapy, J. Controlled Release, 2015 Mar 31; 207:18-30. doi: 10.1016/j.jconrel.2015.03.033. [Epub ahead of print] PMID: 25836593; The most downloaded article in JCR in last 90 days.
  3. Roy U., Hong Ding H., Kanthikeel S.P., Raymond A., Atluri V., Yndart A., Kaftanovskaya E.M., Batrakova E.V., Nair M. (2015) Preparation, Characterization and Efficacy of Anti-HIV Nanodrug Targeting to Microfold cell (M cell) of the Gut-associated lymphoid Tissue (GALT), Int J Nanomedicine. 18;10:5819-35. doi: 10.2147/IJN.S68348. PMID: 26425084.
  4. Kim M.S., Haney M.J., Zhao Y., Gupta R., Mahajan V., Inskoe E., Piroyan A., Sokolsky M., Okolie O., Hingtgen S.D., Kabanov A.V., and Batrakova E.V. (2015) Development of Exosome-encapsulated Paclitaxel to Overcome MDR in Cancer cells, Nanomedicine, Nov 13. pii: S1549-9634(15)00202-6. doi: 10.1016/j.nano.2015.10.012. PMID: 26586551.
  5. Batrakova E.V. and Kim M.S. (2015) Using naturally-equipped nanocarriers, exosomes, for drug delivery, J. Controlled Release, Aug 1. pii: S0168-3659(15)30042-0. doi: 10.1016/j.jconrel.2015.07.030. [Epub ahead of print] PMID: 26241750.
  6. Roy U., Barber P., Tse-Dinh Y.C., Batrakova E.V., Mondal D., and Nair M. (2015) Role of MRP transporters in regulating antimicrobial drug inefficacy and oxidative stress-induced pathogenesis during HIV-1 and TB infections, Frontiers in Microbiology, Front Microbiol. 2015 Sep 17;6:948. doi: 10.3389/fmicb.2015.00948. eCollection 2015: PMID:26441882, [PubMed] PMCID: PMC4585023.
  7. Klyachko N.L., Haney M.H., Zhao Y., Polak R., Cohen R.E., Rubner M.F. and Batrakova E.V. (2015) Monocyte-mediated delivery of polymeric backpacks to inflamed brain tissues, J Control Release, in preparation.
  8. Zhao Y., Haney M.J., Gupta R., Bohnsack J.R., He Z., Kabanov A.V., Batrakova E.V. (2014) GDNF-transfected Macrophages Produce Potent Neuroprotective Effects in Parkinson’s Disease Mouse Model, PLoS One. Sep 17;9(9):PMID: 25229627.
  1. Okolie, O., Bago, J.R., Schmid, R.S., Bash, R., Miller, C.R., Hingtgen, S.D. A murine glioma resection and recurrence model reveals reactive astrocytes potentiate tumor aggressiveness in vitro. J. Neuro-surg (Under Review).
  2. Bago, J.R., Okolie, O., Dumitru, R., Ewend, M.G., Hingtgen, S.D. Tumor-homing Cytotoxic Induced Neural Stem Cells for Cancer Therapy. Sci Transl Med (Under Review).
  3. Bago, J.R., Okolie, O., Alfonso-Pecchio, A., Mohiti-Asli, M., Loboa, E.G., Hingtgen, S.D. Electrospun nanofiberous scaffolds as intra-cavity delivery systems for engineered stem cell therapy of surgically resected glioblastoma. Biomaterials (Under Review).
  4. Bago, J.R., Alfonso-Pecchio, A., Okolie, O., Dumitru, R., Rinkenbaugh, A., Baldwin, A.S., Miller, C.R., Magness, S.T., Hingtgen, S.D. (2016). Therapeutically engineered induced neural stem cells are tumor-homing and inhibit progression of glioblastoma. Nat. Commun., (In Press).
  5. Bago, J.R., Pegna, G.L., Okolie, O., Hingtgen, S.D. (2016). Fibrin matrices enhance the transplant and efficacy of cytotoxic stem cell therapy for post-surgical cancer. Biomaterials (In Press).
  6. Bago, J.R., Sheets, K.T., Hingtgen, S.D. (2015). Neural Stem Cell Therapy for Cancer. Methods. 2015 Aug 24; S1046-2023 doi: 10.1016/j.ymeth.2015.08.013. [Epub ahead of print].
  7. Kim MS, Haney MJ, Zhao Y, Mahajan V, Deygen I, Klyachko NL, Inskoe E, Piroyan A, Sokolsky M, Okolie O, Hingtgen SD, Kabanov AV, Batrakova EV. Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells. Nanomedicine. 2015 Nov 14.
  8. Stuckey D.W.*, Hingtgen S.D.*, Karakas N., Rich B.E., Shah K. Engineering toxin-resistant therapeutic stem cells to treat brain tumors. Stem Cells. 2014 Oct. [Epub]. PMID: 25346520 (PMC Journal in process). *co-first authors.
  9. Duebgen M., Martinez-Quitanilla J., Tamura K., Hingtgen S.D., Redjal N., Wakimoto H., Shah K. Stem cells loaded with multimechanistic oncolytic herpes simplex virus variants for brain tumor therapy. J Natl. Cancer Inst. 2014 May 16; 106 (6) [Epub ahead of print]. PMID: 24838834 (PMC Journal in process).
  1. Lin, G. Zhang, H. and Huang, L. Smart polymeric nanoparticles for cancer gene delivery. Molecular Pharmaceutics, 12:314-321, 2015.
  2. Wang, Y., Miao, L., Satterlee, A. and Huang, L. Delivery of Oligonucleotides with Lipid Nanoparticles. Advanced Drug Delivery Review, 87:68-80, 2015.
  3. Miao, L. and Huang, L. Exploring the Tumor Microenvironment with Nanoparticles. Cancer Treatment and Research, 166, pp 193-226, 2015. Published as a chapter in “Nanotechnology-Based Precision Tools for the Detection and Treatment of Cancer”, ed. C.A. Mirkin et al, Springer International Publishing Switzerland.
  4. Miao, L., Lin, C.M. and Huang, L. Stromal barriers and strategies for the delivery of nanomedicine to desmoplastic tumors. Journal of Controlled Release, 219:192-204, 2015. Epub 2015 Aug 12.
  5. Chen, Y., Gao, D.Y. and Huang, L. In vivo delivery of miRNAs for cancer therapy: Challenges and strategies. Advanced Drug Delivery Reviews, 81:128-141, 2015. Epub 2014 May 22.
  6. Zhang, J., Li, X. and Huang, L. Non-viral nanocarriers for siRNA delivery in breast cancer. J. Controlled Release, 190:440-450, 2014. Epub 2014 May 27. PMCID: PMC4142098.
  7. Goodwin, T. and Huang, L. Nonviral Vectors: We Have Come a Long Way. In “Non-viral Vectors for Gene Therapy: Lipid and Polymer Based Gene Transfer” ed. Huang, L., Liu, D. and Wagner, E. Chapter 1, pp 1-12, 2014, Advances in Genetics, Volume 88, Elsevier Academic Press.
  8. Zhao, Y. and Huang, L. Lipid Nanoparticles for Gene Delivery. In “Non-viral Vectors for Gene Therapy: Lipid and Polymer Based Gene Transfer” ed. Huang, L., Liu, D. and Wagner, E. Chapter 2, pp 13-36, 2014, Advances in Genetics, Volume 88, Elsevier Academic Press.
  9. Wang, Y. and Huang, L. Composite Nanoparticles for Gene Delivery. In “Non-viral Vectors for Gene Therapy: Lipid and Polymer Based Gene Transfer” ed. Huang, L., Liu, D. and Wagner, E. Chapter 5, pp 111-137, 2014, Advances in Genetics, Volume 88, Elsevier Academic Press.
  10. Hayes, M.T. and Huang, L. Lipid-Coated Calcium Phosphate Nanoparticles for Nonviral Gene Therapy. In “Non-viral Vectors for Gene Therapy: Lipid and Polymer Based Gene Transfer” ed. Huang, L., Liu, D. and Wagner, E. Chapter 7, pp 206-229, 2014, Advances in Genetics, Volume 88, Elsevier Academic Press.
  1. J Fu, E Pacyniak, MGD Leed, MP Sadgrove, L Marson and M Jay. Interspecies Differences in the Metabolism of a Multiester Prodrug by Carboxylesterases. J Pharm Sci,, in press.
  2. JE Huckle, E Altun, M Jay and RC Semelka. Gadolinium Deposition In Humans: When Did We Learn That Gadolinium Was Deposited In Vivo? Investigative Radiology, Epub ahead of print.
  3. LMB Burke, M Ramalho, M Al Obaidy, E Chang, MD, E Wu, M Jay and RC Semelka. Self-Reported Gadolinium Toxicity: A Survey of Patients with Chronic Symptoms They Ascribe to Gadolinium Exposure. Submitted to American Journal of Roentgenology.
  4. JE Huckle, MP Sadgrove, Marina GD Leed, YT Yang, RJ Mumper and M Jay. C2E2: A di-ethyl ester prodrug of DTPA as an orally bioavailable radionuclide decorporation agent, Submitted to AAPS Journal.
  5. J Fu, M Sadgrove, L Marson and M Jay. Biotransformation capacity of carboxylesterase in skin and keratinocytes for pentaethyl ester prodrug of DTPA. Submitted to Drug Met Disposition.
  6. JE Huckle, MP Sadgrove, RJ Mumper and M Jay. Species-Dependent Chelation of 241Am by DTPA Di-ethyl Ester. Health Physics. 108:443-450 (2015).
  7. J Fitzsimmons and M Jay. Preparative scale separation of ethyl esters of diethylenetriaminepentaacetic acid by flash chromatography. J Radioanalytical Nucl Chem. 305:329–336 (2015).
  8. JE Huckle, MP Sadgrove, E Pacyniak, MGD Leed, WM Weber, M Doyle-Eisele, RA Guilmette, BJ Agha, RL Susick, RJ Mumper and M Jay. Orally Administered DTPA Di-ethyl Ester for Decorporation of 241Am: Efficacy in a Dog Inhalation-Contamination Model and Safety Assessment in Dogs. Int J Rad Biol., 91(7):568-75 (2015).
  9. P Phetpornpaisan, P Tippayawat, M Jay and K Sutthanut. A Local Thai Cultivar Glutinous Black Rice Bran: A Source of Functional Compounds in Immunomodulation, Cell Viability and Collagen Synthesis, and Matrix Metalloproteinase-2 and -9 Inhibition. J Functional Foods. 7:650-661 (2014).
  10. YT Yang, AJ Di Pasqua, Y Zhang, K Sueda and M Jay. Solid dispersions of the penta-ethyl ester prodrug of diethylenetriaminepentaacetic acid (DTPA): formulation design and optimization studies. Pharm Dev Tech. 19:806-812 (2014).
  11. YT Yang, Y Shi, M Jay and AJ Di Pasqua. Enhanced toxicity of cisplatin with chemosensitizer phenethyl isothiocyanate toward non-small cell lung cancer cells when delivered in liposomal nanoparticles. Chem Res Toxicol. 27:946-948 (2014).
  12. K Sueda, MP Sadgrove, JE.Huckle, MGD Leed, WM Weber, M Doyle-Eisele, RA Guilmette and M Jay. Orally Administered DTPA Penta-Ethyl Ester for the Decorporation of Inhaled 241Am. J Pharm Sci. 103:1563–1571 (2014).
  1. Abakumov MA, Nukolova NV, Sokolsky-Papkov M, Shein SA, Sandalova TO, Vishwasrao HM, Grinenko NF, Gubsky IL, Abakumov AM, Kabanov AV, Chekhonin VP (2015) VEGF-targeted magnetic nanoparticles for MRI visualization of brain tumor. Nanomedicine. 11(4):825-33. doi: 10.1016/j.nano.2014.12.011. Epub 2015 Jan 31.
  2. Filatova LY, Donovan DM, Foster-Frey J, Pugachev VG, Dmitrieva NF, Chubar TA, Klyachko NL, Kabanov AV (2015) Bacteriophage phi11 lysin: Physicochemical characterization and comparison with phage phi80α lysine. Enzyme Microb Technol. 2015 Jun;73-74:51-8. doi: 10.1016/j.enzmictec.2015.03.005. Epub 2015 Apr 8.
  3. Golovin YI, Gribanovsky SL, Golovin DY, Klyachko NL, Majouga AG, Master АM, Sokolsky M, Kabanov AV (2015) Towards nanomedicines of the future: Remote magneto-mechanical actuation of nanomedicines by alternating magnetic fields. J Control Release. pii: S0168-3659(15)30138-3. doi: 10.1016/j.jconrel.2015.09.038. [Epub ahead of print].
  4. Golovin Yu I, Klyachko NL, Gribanovskii SL, Golovin DYu, Samodurov AA, Majouga AG, Sokolsky-Papkov M, Kabanov AV (2015) Nanomechanical control of properties of biological membranes achieved by rodlike magnetic nanoparticles in a superlow-frequency magnetic field. Technical Physics Letters 41(5):455-457.
  5. Haney MJ, Klyachko NL, Zhao Y, Gupta R, Plotnikova EG, He Z, Patel T, Piroyan A, Sokolsky M, Kabanov AV, Batrakova EV (2015) Exosomes as drug delivery vehicles for Parkinson’s disease therapy. J. Control Release 207:18-30. doi: 10.1016/j.jconrel.2015.03.033. Epub 2015 Mar 31.
  6. He Z, Schulz A, Wan X, Seitz J, Bludau H, Alakhova DY, Darr DB, Perou CM, Jordan R, Ojima I, Kabanov AV, Luxenhofer R. (2015) Poly(2-oxazoline) based micelles with high capacity for 3rd generation taxoids: preparation, in vitro and in vivo evaluation. J Control Release. 208:67-75. doi: 10.1016/j.jconrel.2015.02.024.
  7. He Z, Miao L, Jordan R, S-Manickam D, Luxenhofer R, Kabanov AV (2015) A Low protein binding cationic poly(2-oxazoline) as non-viral vector. Macromol Biosci. 15(7):1004-20. doi: 10.1002/mabi.201500021.
  8. Jiang Y, Brynskikh AM, Devika S, Kabanov AV (2015) SOD1 nanozyme salvages ischemic brain by locally protecting cerebral vasculature, J Control Release, 213:36-44. doi: 10.1016/j.jconrel.2015.06.021.
  9. Kim MS, Haney MJ, Zhao Y, Mahajan V, Deygen I, Klyachko NL, Inskoe E, Piroyan A, Sokolsky M, Okolie O, Hingtgen SD, Kabanov AV, Batrakova EV. (2015) Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells. Nanomedicine. 2015 Nov 14. pii: S1549-9634(15)00202-6. doi: 10.1016/j.nano.2015.10.012. [Epub ahead of print].
  10. Kost OA, Beznos OV, Davydova NG, Manickam DS, Nikolskaya II, Guller AE, Binevski PV, Chesnokova NB, Shekhter AB, Klyachko NL, Kabanov AV (2015) Superoxide Dismutase 1 Nanozyme for Treatment of Eye Inflammation, Oxidative Medicine and Cellular Longevity, 2015:5194239. doi: 10.1155/2016/5194239. Epub 2015 Dec 1.
  11. Majouga A, Sokolsky-Papkov M, Kuznetsov A, Lebedev D, Efremova M, Beloglazkina E, Rudakovskaya P, Veselov M, Zyk N, Golovin Y, Klyachko N, Kabanov A. (2015) Enzyme-functionalized gold-coated magnetite nanoparticles as novel hybrid nanomaterials: Synthesis, purification and control of enzyme function by low-frequency magnetic field. Colloids Surf B Biointerfaces. 125:104-9. doi: 10.1016/j.colsurfb.2014.11.012. Epub 2014 Nov 20. PMID: 25460600.
  12. Mitragotri S, Anderson DG, Chen X, Chow EK, Ho D, Kabanov AV, Karp JM, Kataoka K, Mirkin CA, Petrosko SH, Shi J, Stevens MM, Sun S, Teoh S, Venkatraman SS, Xia Y, Wang S, Gu Z, Xu C (2015) Accelerating the Translation of Nanomaterials in Biomedicine. ACS Nano 9(7):6644-54. doi: 10.1021/acsnano.5b03569.
  13. Rudakovskaya PG, Beloglazkina EK, Majouga AG, Klyachko NL, Kabanov AV, Zyk NV (2015) Synthesis of magnetite-gold nanoparticles with core-shell structure. Moscow University Chemistry Bulletin, 70(3):149-156.
  14. Semkina A, Abakumov M, Grinenko N, Abakumov A, Skorikov A, Mironova E, Davydova G, Majouga AG, Nukolova N, Kabanov A, Chekhonin V (2015) Core-Shell-Corona Doxorubicin-Loaded Superparamagnetic Fe3O4 Nanoparticles for Cancer Theranostics, Colloids and Surfaces B: Biointerfaces, Publication date 2015/11/10.
  15. Seo Y, Schulz A, Han Y, He Z, Bludau H, Wan X, Tong J, Bronich TK, Sokolsky M, Luxenhofer R, Jordan R, Kabanov AV (2015) Poly (2‐oxazoline) block copolymer based formulations of taxanes: effect of copolymer and drug structure, concentration, and environmental factors, J Polymers Adv Technologies, 26 (7), 837-50.
  16. Abakumova T, Abakumov M, Shein S, Chelushkin P, Bychkov D, Mukhin V, Yusubalieva G, Grinenko N, Kabanov A, Nukolova N, Chekhonin V. (2016) Connexin 43-targeted T1 contrast agent for MRI diagnosis of glioma. Contrast Media Mol Imaging. 11(1):15-23 doi: 10.1002/cmmi.1653. [Epub ahead of print].
  17. Mahajan V, Gaymalov Z, Alakhova D, Gupta R, Zucker IH, Kabanov AV (2016) Horizontal gene transfer from macrophages to ischemic muscles upon delivery of naked DNA with Pluronic block copolymers, Biomaterials 75:58-70. doi: 10.1016/j.biomaterials.2015.10.002.
  18. Perriotte-Olson C, Adi N, Manickam DS, Westwood RA, Desouza CV, Natarajan G, Crook A, Kabanov AV, Saraswathi V. (2016) Nanoformulated copper/zinc superoxide dismutase reduces adipose inflammation in obesity. Obesity 24(1):148-56. doi: 10.1002/oby.21348. Epub 2015 Nov 27.
  19. Saraswathi V, Ganesan M, Perriotte-Olson C, Manickam DS, Westwood RA, Zimmerman MC, Ahmad IM, Desouza CV, Kabanov AV. (2016) Nanoformulated copper/zinc superoxide dismutase attenuates vascular cell activation and aortic inflammation in obesity. Biochem. Biophys. Res. Commun. 469(3):495-500. doi: 10.1016/j.bbrc.2015.12.027. Epub 2015 Dec 12.
  20. Falcone, J.A., Salameh, T.S., Yi, X., Cordy, B.J., Mortell, W.G., Kabanov, A.V., Banks, W.A. (2014) Intranasal administration as a route for drug delivery to the brain: evidence for a unique pathway for albumin. J Pharmacol. Exp. Ther. 351(1):54-60. doi: 10.1124/jpet.114.216705. Epub 2014 Jul 15. PMCID: PMC4165023.
  21. Filatova, L.Yu., Donovan, D.M., Becker, S.C., Priyma, A.D., Kabanov, A.V., Klyachko, N.L. (2014) An investigation of the structure and function of antistaphylococcal endolysins using kinetic methods. Moscow University Chemistry Bulletin 69 (3), 107-111.
  22. Legotsky, S.A., Vlasova, K.Y., Priyma, A.D., Shneider, M.M., Pugachev, V.G., Totmenina, O.D., Kabanov, A.V., Miroshnikov, K.A., Klyachko, N.L. (2014) Peptidoglycan degrading activity of the broad-range Salmonella bacteriophage S-394 recombinant endolysin. Biochimie. 2014 Sep 18. pii: S0300-9084(14)00266-1. doi: 10.1016/j.biochi.2014.09.017. [Epub ahead of print] PMID: 25241254.
  23. Lyagin, I.V., Efremenko, E.N., Kabanov A.V. (2014) Catalytic characteristics of enzyme-polyelectrolyte complexes based on hexahistidine-containing organophosphorus hydrolase, Moscow University Chemistry Bulletin 69 (3), 125-130.
  24. Majouga, A.G., Zvereva, M.I., Rubtsova, M.P., Skvortsov, D.A., Mironov, A.V., Azhibek, D.M., Krasnovskaya, O.O., Gerasimov, V.M., Udina, A.V., Vorozhtsov, N.I., Beloglazkina, E.K., Agron, L.A., Mikhina, L.V., Tretyakova, A.V., Zyk, N.V., Zefirov, N.S., Kabanov, A.V., Dontsova, O.A. (2014) Mixed valence copper (I,II) binuclear complexes with unexpected structure: synthesis, biological properties and anticancer activity. 57 (14), 6252-8. doi: 10.1021/jm500154f PMID: 24950478.
  25. Nukolova, N.V., Baklaushev, V.P., Abakumova, T.O., Mel’nikov, P.A., Abakumov, M.A., Yusubalieva, G.M., Bychkov, D.A., Kabanov, A.V., Chekhonin, V.P. (2014) Targeted delivery of cisplatin by сonnexin 43 vector nanogels to the focus of experimental glioma C6. Bull Exp Biol Med. 157 (4), 524-9. doi: 10.1007/s10517-014-2606-x. Epub 2014 Aug 12. PMID: 25110098.
  26. Panina, I.S, Filatova, L.Y., Kabanov, A.V., Klyachko, N.L. (2014) An investigation of the physicochemical properties of both glutathione peroxidase I and its complexes with polyelectrolytes as promising agents for the treatment of diseases of the central nervous system. Moscow University Chemistry Bulletin 69 (3), 112-116.
  27. Savalia, K., Manickam, D.S., Rosenbaugh, E.G., Tian, J., Ahmad, I.M., Kabanov, A.V., Zimmerman, M.C. (2014) Neuronal uptake of nanoformulated superoxide dismutase and attenuation of angiotensin II-dependent hypertension after central administration. Free Radic. Biol. Med. 73:299-307. doi: 10.1016/j.freeradbiomed.2014.06.001. PMCID: PMC4116739.
  28. Schulz, A., Jaksch, S., Schubel, R., Wegener, E., Di, Z., Han, Y., Meister, A., Kressler, J., Kabanov, A.V., Luxenhofer, R., Papadakis, C.M., Jordan R. (2014) Drug-induced morphology switch in drug delivery systems based on poly(2-oxazoline)s. ACS Nano 8 (3), 2686–96. DOI: 10.1021/nn406388t PMCID: PMC4004286.
  29. Singh, D., McMillan, J.M., Liu, X.-M., Vishwasrao, H.M., Kabanov A.V., Sokolsky-Papkov, M., Gendelman, H.E. (2014) Formulation design facilitates magnetic nanoparticle delivery to diseased cells and tissues. Nanomedicine, 9 (3), 469-85. doi: 10.2217/nnm.14.4. PMID: 24646020.
  30. Singh, D., McMillan, J.M., Liu, X.-M., Vishwasrao, H.M., Kabanov A.V., Sokolsky-Papkov, M., Gendelman, H.E. (2014) Bench-to-bedside translation of magnetic nanoparticles. Nanomedicine, 9 (4), 501-16. doi: 10.2217/NMM.14.5. PMCID: PMC4150086.
  31. Yi, X., Manickam, D.S., Brynskikh, A., Kabanov, A.V. (2014) Agile delivery of protein therapeutics to CNS. J. Control. Release. 190:637-63, doi: 10.1016/j.jconrel.2014.06.017. PMCID: PMC4142106.
  32. Yi, X., Yuan, D., Farr, S.A., Banks, W.A., Poon, C.D., Kabanov, A.V. (2014) Pluronic modified leptin with increased systemic circulation, brain uptake and efficacy for treatment of obesity. J. Control. Release. 191, 34-46 doi: 10.1016/j.jconrel.2014.05.044. PMCID: PMC4197010.
  33. Zhao, Y., Haney, M.J., Gupta, R., Bohnsack, J.P., He, Z., Kabanov, A.V., Batrakova, E.V. (2014) GDNF-transfected macrophages produce potent neuroprotective effects in Parkinson’s disease mouse model. PLoS One. 2014 Sep 17;9(9):e106867. doi: 10.1371/journal.pone.0106867. eCollection 2014. PMCID: PMC4167552.
  1. Wessler T, Chen A, McKinley SA, Cone R, Forest MG, Lai SK. (2015) Using computational modeling to optimize the design of antibodies that trap viruses in mucus. ACS Infectious Disease. DOI: 10.1021/acsinfecdis.5b00108.
  2. Yang Q*, Parker C*, McCallen J, Lai SK§. (2015) Addressing challenges of heterogeneous tumor treatment using bispecific protein-mediated pretargeted drug delivery. J Controlled Release. DOI:10.1016/j.jconrel.2015.09.040 [Impact 7.16]
  3. Wang YY, Nunn KL, McKinley S, Lai SK§. (2015) Minimizing biases associated with tracking analysis of submicron particles in heterogeneous biological fluids. J Controlled Release. 220:37-43. [Impact 7.16].
  4. Nunn KL, Wang YY, Harit D, Humphrys M, Ma B, Cone R, Ravel J, Lai SK§. (2015) Enhanced trapping of HIV-1 by human cervicovaginal mucus is associated with Lactobacillus crispatus-dominant microbiota. mBio. 6(5):e01084-1 [Impact: 6.79].
  5. Chen A, McKinley SA, Shi F, Wang S, Mucha PJ, Harit D, Forest MG, Lai SK§. (2015) Modeling of Virion Collisions in Cervicovaginal Mucus Reveals Limits on Agglutination as the Protective Mechanism of Secretory Immunoglobulin A. PLoS ONE. 10(7):e0131351 [Impact 4.41].
  6. Yang Q, Lai SK§. (2015) Emergence, characteristics and unaddressed questions about anti-PEG immunity. WIREs Nanomedicine & Nanobiotechnology (Invited Review). 7(5):655-77. [Impact 4.24] {Cited 3}.
  7. McKinley SA, Chen A, Shi F, Wang S, Mucha P, Forest MG, Lai SK. (2014) Modeling neutralization kinetics of HIV-1 by broadly neutralizing monoclonal antibodies in genital secretions coating the cervicovaginal mucosa. PLoS ONE. 9(6):e100598 [Impact 4.41] {Cited 7}.
  8. Chen A, McKinley SA, Shi F, Wang S, Mucha P, Forest MG, Lai SK. (2014) Transient antibody-mucin interactions produce a dynamic molecular shield against viral invasion. Biophysical Journal. 106(9):2028-2036. [Impact 3.7] {Cited 7}.
  9. Yang Q, Jones SW, Parker C, Zamboni WC, Jear JE, Lai SK§. (2014) Evading immune cell uptake and clearance requires PEG grafting at densities markedly exceeding the minimum for brush conformation. Molecular Pharmaceutics. 11(4):1250-8   [Impact 4.6] {Cited 25}.
  10. Wang YY*, Kannan A*, Nunn KL, Murphy M, Subramani DB, Moench TM, Cone RA, Lai SK§. (2014) IgG in cervicovaginal mucus traps HSV and prevents vaginal Herpes infections. Mucosal Immunology. 7, 1036–1044 [Impact 7.5] {Cited 12}.
  1. GN Asher, JK Fallon, PC Smith.   UGT concentrations in human rectal tissue after multidose, oral curcumin. Pharmacol Res Perspectives (in press).
  2. KM Knights, SM Spencer, JK Fallon, N Chau, PC Smith, JO Miners.   Scaling factors for the in vitro-in vivo extrapolation (IV-IVE) of renal drug and xenobiotic glucuronidation clearance. Br J Clin Pharmacol. 2016 Jan 25. PMID: 26808419.
  3. G Margaillan, M Rouleau, K Klein, JK Fallon, P Caron, L Villeneuve, PC Smith, UM Zanger, C Guillemette. Multiplexed Targeted Quantitative Proteomics Predicts Hepatic Glucuronidation Potential.   Drug Metab Dispos. Sep;43(9):1331-1335. (2015).   PMID: 26076694.
  4. G Margaillan, M Rouleau, JK Fallon, P Caron, LVilleneuve, V Turcotte, PC Smith, MS Joy, and C Guillemette. Quantitative profiling of human renal UDP-glucuronosyltransferases and glucuronidation activity: A comparison of normal and tumoral kidney tissues,   Drug Metab Dispos 43:611–619, (2015)   PMID: 25650382.
  5. JW Higgins, JQ Bao, AB Ke, JR Manro, JK Fallon, PC Smith, MJ Zamek-Gliszczynski. Utility of Oatp1a/1b-knockout and OATP1B1/3-humanized mice in the study of OATP-mediated pharmacokinetics and tissue distribution: case studies with pravastatin, atorvastatin, simvastatin, and carboxydichlorofluorescein.   Drug Metab Dispos. 42(1):182-92 (2014). PMID: 24194513.
  1. Ling C, Wang Y, Lu Y, Wang L, Jayandharan GR, Aslanidi GV, Li B, Cheng B, Ma W, Lentz T, Ling C, Xiao X, Samulski RJ, Muzyczka N, Srivastava A. (2015) Enhanced transgene expression from recombinant single-stranded d-sequence-substituted adeno-associated virus vectors in human cell lines in vitro and in murine hepatocytes in vivo. Journal Virol. ;89(2):952-61.
  2. Chunxia Zhao, Chunping Qiao, Ruhang Tang, Jiangang Jiang, Jianbin Li, Carrie Bette Martin, Karen Bulaklak, Juan Li, Dao Wen Wang, and Xiao Xiao (2015) Overcoming insulin insufficiency by forced follistatin expression in beta-cells of DB/DB mice. Molecular Therapy, 23(5):866-74.
  3. He B, Cruz-Topete D, Oakley RH, Xiao X, Cidlowski JA. (2015) Human Glucocorticoid Receptor β (hGRβ) Regulates Gluconeogenesis and Inflammation in Mouse Liver. Mol Cell Biol. pii: MCB.00908-15. [Epub ahead of print].
  4. Berns KI, Byrne BJ, Flotte TR, Gao G, Hauswirth WW, Herzog RW, Muzyczka N, VandenDriessche T, Xiao X, Zolotukhin S, Srivastava A. (2015) Adeno-Associated Virus Type 2 and Hepatocellular Carcinoma? Hum Gene Ther. 26(12):779-81.
  5. Lenhart KC, O’Neill TJ 4th, Cheng Z, Dee R, Demonbreun AR, Li J, Xiao X, McNally EM, Mack CP, Taylor JM. (2015) GRAF1 deficiency blunts sarcolemmal injury repair and exacerbates cardiac and skeletal muscle pathology in dystrophin-deficient mice. Skelet Muscle. 5:27.
  6. HI Ma, HA Shui, CH Wang, CY Wang, DY Huang, SH Chiou, HM Chen, J Li, SY Cheng, X Xiao, YP Yang (2014) Intratumoral decorin gene delivery by AAV vector inhibits brain glioblastomas and prolongs survival of animals by inducing cell differentiation, International Journal of Molecular Sciences (IJMS) 15(3):4393-414.
  7. Qiao C, Wang CH, Zhao C, Lu P, Awano H, Xiao B, Li J, Yuan Z, Dai Y, Martin CB, Li J, Lu Q, Xiao X. (2014) Muscle and heart function restoration in a limb girdle muscular dystrophy 2I (LGMD2I) mouse model by systemic FKRP gene delivery. Mol Ther. [Epub ahead of print].
  8. Lenhart KC, Becherer AL, Li J, Xiao X, McNally EM, Mack CP, Taylor JM (2014) GRAF1 promotes ferlin-dependent myoblast fusion. Dev Biol. Jul 11. [Epub ahead of print].
  9. Vannoy CH, Xu L, Keramaris E, Lu P, Xiao X, Lu QL. (2014) Adeno-Associated Virus-Mediated Overexpression of LARGE Rescues α-Dystroglycan Function in Dystrophic Mice with Mutations in the Fukutin-Related Protein. Hum Gene Ther Methods. 2014 Jun;25(3):187-96.
  10. Catherine Gérard1, Xiao Xiao2, Zoé Coulombe1, Marie Arsenault3, Jacques Couet3, Juan Li2, Marie-Claude.Drolet3, Pierre Chapdelaine1, Amina Chikh1 and Jacques P. Tremblay1 (2014) An AAV9 coding for frataxin clearly improved symptoms and prolonged the life of mouse models of Friedreich ataxia. Mol Ther. Methods & Clinical Development Published online 08 October 2014.

 More Information on Our Faculty and Their Research